Related Experiment Video
Updated: Mar 6, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Infections in Patients with a Total Artificial Heart Are Common but Rarely Fatal
Luis F Hidalgo1, Keyur B Shah, Richard H Cooke
1From the *Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York; †Department of Medicine, Division of Cardiology, Virginia Commonwealth University Medical Center, Richmond, Virginia; and ‡Department of Surgery, Division of Cardiothoracic Surgery, Virginia Commonwealth University Medical Center, Richmond, Virginia.
Insights
Total artificial heart (TAH) recipients experienced frequent infections, primarily urinary and respiratory tract infections. However, mortality directly linked to these infections was uncommon, with most patients undergoing heart transplantation.
Area of Science:
- Cardiology
- Infectious Diseases
- Medical Devices
Background:
- Total artificial heart (TAH) implantation is a critical intervention for end-stage heart failure.
- Understanding infection risks and patterns in TAH recipients is crucial for patient management.
Purpose of the Study:
- To analyze the incidence, sources, and pathogens of infections in patients receiving a TAH.
- To evaluate the impact of infections on outcomes, including mortality and heart transplantation.
Main Methods:
- Retrospective analysis of patients who received a TAH at Virginia Commonwealth University (VCU) between 2010 and 2011.
- Data extraction from the VCU Mechanical Circulatory Support Clinical Database and medical records.
- Classification of infections as confirmed or suspected, with identification of sources and pathogens.
Main Results:
- 32 patients received a TAH, with a mean support duration of 225 days.
- 78% of patients developed infections, most commonly urinary tract (26), respiratory tract (18), and bloodstream (11).
- Klebsiella pneumoniae, coagulase-negative Staphylococci, Enterococcus, and Enterobacter were the most frequent pathogens. Mortality directly attributable to infection was infrequent.
Conclusions:
- Infections are highly prevalent in TAH recipients.
- While common, infections in this cohort did not frequently lead to death, suggesting effective management strategies.
- Further research into infection prevention and treatment in TAH patients is warranted.
Abstract:
Patients who received a total artificial heart (TAH) at Virginia Commonwealth University (VCU) between January 1, 2010 and December 31, 2011 were identified from the VCU Mechanical Circulatory Support Clinical Database. Retrospective data extraction from the medical records was performed from the time of TAH implantation until heart transplantation or death. Infections were classified as confirmed or suspected. Twenty-seven men and five women, mean age 49.5 years (range 24-68 years) received a TAH. The mean duration of TAH support was 225 days (range 1-1,334 days). Of the 32 patients, 4 (12.5%) died and 28 (87.5 %) underwent heart transplantation. Causes of death were pneumonia (n = 1), TAH malfunction (n = 1), refractory cardiogenic shock (n = 1), and respiratory failure (n = 1). Seventy documented and 13 suspected infections developed in 25 patients (78%). The most common sources of infection were urinary tract (n = 26), respiratory tract (n = 18), and bloodstream (n = 11). There were five pump infections and two driveline infections. The number of infections per patient ranged from 0 to 10. Sixteen different pathogens were identified; the most common were: Klebsiella pneumoniae (n = 15), coagulase-negative Staphylococci (n = 10), Enterococcus species (n = 9), and Enterobacter species (n = 8). Mortality directly attributable to infection was infrequent.
Related Concept Videos
Endocarditis I: Introduction
Endocarditis IV: Nursing Management
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
Endocarditis III: Medical Management
Cardiac Catheterization II: Right Heart Catheterization
Endocarditis II: Clinical Features of Infective Endocarditis

